Viramune Labeling Revised To Require Liver Monitoring In First 12 Weeks
Executive Summary
Revised black box labeling for Boehringer Ingelheim/Roxane antiretroviral Viramune (nevirapine) states that patients must receive liver monitoring during the first 12 weeks of therapy.